Why the study?
Determining cost-utility differences between home-based cardiac rehabilitation and usual post-discharge care can improve resource-allocation in healthcare settings.
Does home-based cardiac rehabilitation improve quality-adjusted life years and reduce costs compared to usual post-discharge care in cardiac patients?
Does home-based cardiac rehabilitation improve quality-adjusted life years and reduce costs compared to usual post-discharge care in cardiac patients?
Home-based cardiac rehabilitation is a cost-effective, dominant strategy that improves quality-adjusted life years compared to usual care, with particular cost and QALY benefits in heart failure patients.
Supports HBCR adoption in post-discharge care; extends cost-utility dominance evidence to cardiac populations.
INTRODUCTION: Determining cost-utility differences between home-based cardiac rehabilitation (HBCR) on the one hand, and usual post-discharge care (UC) on the other, can improve resource-allocation in healthcare settings. AREAS COVERED: In June 2019, PubMed, Web of Science, Scopus, and Cochrane library were searched for randomized controlled HBCR trials. Standardized mean differences (SMDs) of cost and quality-adjusted life years (QALYs) between HBCRs and UCs were calculated using random effect models. Heterogeneity was assessed by inconsistency index (I2) and publication bias by funnel plot and Egger's regression test. Thirteen articles, representing 2,992 participants, were deemed representative for final analysis. In the meta-analysis, a significant difference with respect to QALYs favored HBCR, while no significant cost difference was observed between HBCR and UC. However, subgroup-analysis of trials with different follow-up durations revealed somewhat different results, and HBCR was found to be significantly better with regard to both cost and QALYs for patients with heart failure. Cost-utility analysis categorizing interventions as 'dominant', 'effective', 'doubtful', and 'dominated', found HBCRs dominant. EXPERT OPINION: Although HBCR tended to be superior compared to UC in this review, larger and more robust trials addressing specific patients groups are needed for definitive results.
No takes yet. Share an insight, caveat, or question.
Bakhshayesh et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: